All the news

Checkpoint inhibitor immunotherapy combinations may slow disease progression in people with hepatocellular carcinoma (HCC), according to two small studies presented at the 2019 Gastrointestinal Cancers Symposium last month in San Francisco. However, response ...

Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ...

The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ...

People with liver cirrhosis and their families need more information about their condition and prognosis and greater access to palliative care, a systematic review of studies on the needs of people with cirrhosis ...

Combining sorafenib (Nexavar) with internal radiation therapy or transarterial chemoembolization did not improve overall survival for people with liver cancer, but it did appear to help certain groups of patients, according to research presented ...